B
Boris Baricky
Publications - 1
Citations - 253
Boris Baricky is an academic researcher. The author has contributed to research in topics: Placebo & Janus kinase inhibitor. The author has an hindex of 1, co-authored 1 publications receiving 219 citations.
Papers
More filters
Journal ArticleDOI
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn,Subrata Ghosh,Julián Panés,Ivana Vranic,Wenjin Wang,Wojciech Niezychowski,Severine Vermeire,Olivier Dewit,Harald Peeters,Jiri Stehlik,Tomas Vanasek,David Laharie,Jean-Frederic Colombel,Marc-André Bigard,Marta Varga,Margit Zeher,Janos Novak,Béla Hunyady,Ágnes Salamon,István Rácz,Paolo Gionchetti,Anna Kohn,Cosimo Prantera,Pieter C. F. Stokkers,Maria Slomka,Leszek Paradowski,Tomasz Arlukowicz,Ladislav Kuzela,Boris Baricky,Tibor Hlavaty,Maria Isabel Vera,Jordi Guardiola,Chris Probert,Jonathan Shaffer,Mark R. Fleisher,Ronald E. Pruitt,John Sawyer Goff,John Weber,Raymond Lloyd Bell,Andrew Harrison Zwick,Alexandra Gutierrez,Robert H. Levine,Stephen Brett Hanauer,Lori Ann Lavelle,Ravindranath K. Kottoor,Gerald W. Dryden,Robert Hardi,David Vaughn Glorioso,Prabhakar Swaroop,Scott D. Lee,Teressa Joan Patrick,Sheldon Scheinert,Charles A. Sninsky,Seymour Katz,Mark D. Noar,Michael Marion Gaspari,Glenn L. Gordon,Thomas A. Dalton,Douglas Edward Homoky,William Ransom Kilgore,Joel A. Levien,Herbert R. Schneider,Suleman Abdul Moola,Frederik Cornelius Kruger,John P. Wright,Nazimuddin Aboo +65 more
TL;DR: There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib or placebo twice daily.